citalopram has been researched along with Constipation in 2 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 9.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
| "This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder." | 5.11 | A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. ( Bothmer, J; Huusom, AK; Montgomery, SA, 2004) |
| "Escitalopram was used as a control for assay sensitivity." | 2.75 | A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. ( Dellva, MA; Dubé, S; Jones, M; Kielbasa, W; Padich, R; Rao, P; Saha, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubé, S | 1 |
| Dellva, MA | 1 |
| Jones, M | 1 |
| Kielbasa, W | 1 |
| Padich, R | 1 |
| Saha, A | 1 |
| Rao, P | 1 |
| Montgomery, SA | 1 |
| Huusom, AK | 1 |
| Bothmer, J | 1 |
2 trials available for citalopram and Constipation
| Article | Year |
|---|---|
A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Citalopram; Constipati | 2010 |
A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Constipation; Cyclohexanols; Delayed-Ac | 2004 |